Elsevier Inc.

SHERPA: Unknown

People

  1. Drilon
    Drilon
  2. Kris
    Kris
  3. Yu
    Yu
  4. Riely
    Riely
  5. Chaft
    Chaft
  6. Rudin
    Rudin
  7. Lesokhin
    Lesokhin
  8. Paik
    Paik
  9. Plodkowski
    Plodkowski
  10. Postow
    Postow

Groups

  1. Department of Medicine (37)
  2. Solid Tumor Oncology Division (37)
  3. Thoracic Oncology (37)
  4. GSK Faculty (6)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  6. Gastrointestinal Oncology Service (4)
  7. Radiology, Department of (4)
  8. Body Imaging Service (2)
  9. Center for Hematologic Malignancies (2)
  10. Center for Pancreatic Cancer Research (2)
Search Within
  1. "European Journal of Cancer"
  2. "Thoracic Oncology"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (6)
  3. Conference Paper (2)
Groups
  1. Department of Medicine (37)
  2. Solid Tumor Oncology Division (37)
  3. Thoracic Oncology (37)
  4. GSK Faculty (6)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  6. Gastrointestinal Oncology Service (4)

More Groups

People
  1. Alexander Drilon (11)
  2. Matthew Hellmann (7)
  3. Helena Yu (5)
  4. Mark Kris (5)
  5. Charles Rudin (4)
  6. Gregory Riely (4)

More People

Years
  1. 2023 (1)
  2. 2022 (5)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. European Journal of Cancer (37)

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
    Journal Article

    Repetto, M.; Crimini, E.; Belli, C.; Boscolo Bielo, L.; Ascione, L.; Meric-Bernstam, F.; Drilon, A.; Curigliano, G.
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 study of MLN0128 (TAK-228) in patients with tumors with TSC1 or TSC2 mutations: Sub-protocol EAY131-M
    Meeting Abstract

    Hays, J.; Song, Z.; Paik, P.; Iyer, G.; Mitchell, E.; Wright, J.; Doyle, L.; Gray, R.; Wang, V.; McShane, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
    Meeting Abstract

    Drilon, A.; Besse, B.; Camidge, D. R.; Ou, S. H. I.; Gadgeel, S. M.; Johnson, M. L.; Calles, A.; de Miguel, M. J.; Spira, A. I.; Felip, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Cho, B. C.; Lin, J.; Camidge, D. R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K. H.; Kim, S. W.; Kao, S.; Diadziuskzko, R.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Update from the ongoing phase 1/2 registrational trial of repotrectinib: Results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)
    Meeting Abstract

    Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y. C.; Lu, S.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
    Journal Article

    Tan, D. S. W.; Kim, S. W.; Ponce Aix, S.; Sequist, L. V.; Smit, E. F.; Yang, J. C. H.; Hida, T.; Toyozawa, R.; Felip, E.; Wolf, J.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
    Journal Article

    Mezquita, L.; Preeshagul, I.; Auclin, E.; Saravia, D.; Hendriks, L.; Rizvi, H.; Park, W.; Nadal, E.; Martin-Romano, P.; Ruffinelli, J. C.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in advanced/ metastatic non-small-cell lung cancer (NSCLC) harboring KRAS G12C mutation
    Meeting Abstract

    Jänne, P. A.; Rybkin, I. I.; Spira, A. I.; Riely, G. J.; Papadopoulos, K. P.; Sabari, J. K.; Johnson, M. L.; Heist, R. S.; Bazhenova, L.; Barve, M.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: A retrospective international multicentre study
    Journal Article

    Lai, W. V.; Lebas, L.; Barnes, T. A.; Milia, J.; Ni, A.; Gautschi, O.; Peters, S.; Ferrara, R.; Plodkowski, A. J.; Kavanagh, J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
    Journal Article

    Tio, M.; Rai, R.; Ezeoke, O. M.; McQuade, J. L.; Zimmer, L.; Khoo, C.; Park, J. J.; Spain, L.; Turajlic, S.; Ardolino, L.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save